You are viewing: Europe Oral Proteins & Peptides Market analysis

The Europe Oral Proteins & Peptides Market was valued at $1226.7 Million in 2025 and projected to reach to $3180.3 Million by 2030, representing a compound annual growth rate of 21.0%. Europe's oral proteins and peptides market is poised for sustained expansion driven by increasing prevalence of chronic diseases, growing demand for non-invasive drug delivery systems, and significant investments in biotechnology innovation.

Europe Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Oral Proteins & Peptides Market Trends and Insights

  • This represents a compound annual growth rate of 21.0%, reflecting strong demand across Europe for innovative oral delivery solutions in therapeutics and nutraceuticals.
  • Europe's advanced healthcare infrastructure, regulatory frameworks, and investment in biotechnology are driving adoption of oral protein and peptide formulations across the region. The European market benefits from increasing prevalence of chronic diseases, aging populations, and growing consumer awareness of protein-based therapeutics.
  • Europe's pharmaceutical and biotech sectors are actively developing next-generation oral delivery technologies to overcome bioavailability challenges.
  • Between 2025 and 2030, Europe is expected to capture significant market share as manufacturers scale production and regulatory approvals accelerate across EU member states and the broader European region..

Key Market Statistics

  • CAGR (2025-2030) 21.0% CAGR
  • Market Size, 2025 ~USD 1226.7 Million
  • Forecast, 2030 ~USD 3180.3 Million
  • Geography Europe

Europe Oral Proteins & Peptides Market Overview

Market Valuation & Growth :

Europe's oral proteins and peptides market is valued at USD 1,226.7 million in 2025, with a projected CAGR of 21.0% through 2030, reaching USD 3,180.3 million. This growth trajectory underscores strong regional demand for advanced oral delivery technologies.

Regulatory Excellence & Infrastructure :

Europe benefits from a mature regulatory framework and advanced healthcare infrastructure that supports rapid innovation and commercialization of oral protein and peptide therapeutics, positioning the region as a leader in pharmaceutical development.

Germany's Market Leadership :

Germany dominates Europe's market with USD 1,418.6 million in market size, reflecting its robust pharmaceutical sector, strong R&D capabilities, and established manufacturing excellence in biopharmaceuticals.

Diverse Market Composition :

The European market comprises key markets including UK (USD 884.5M), France (USD 391.9M), Italy (USD 247.4M), and Spain (USD 147.8M), alongside emerging opportunities in the broader European region valued at USD 244.4 million.

Europe Oral Proteins & Peptides Market Dynamics

  • The region's stringent regulatory standards and advanced healthcare systems create a favorable environment for novel therapeutic development and commercialization. Key growth drivers include rising patient preference for oral formulations, expanding geriatric populations requiring chronic disease management, and collaborative efforts between pharmaceutical companies and research institutions.
  • Europe's commitment to precision medicine and personalized therapeutics further accelerates market penetration, with particular momentum in Germany, UK, and France leading regional development..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Europe's oral proteins & peptides market is valued at USD 1,226.7 million in 2025, with a projected CAGR of 21.0% through 2030.
    • The market is expected to grow to USD 3,180.3 million by 2030, driven by advanced healthcare infrastructure and biotech innovation across Europe.
    • Europe's aging population and rising chronic disease prevalence are key growth catalysts for oral protein and peptide therapeutics.
    • Regulatory support and investment in oral delivery technologies position Europe as a leading market for next-generation protein formulations.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Europe Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS404.4704.6892.21064.71271.51525.41838.3222620.1
    HOSPITALS & SPECIALTY CLINICS111.6190.9236.9276.9323.9380.3448.4531.117.5
    LONG-TERM CARE FACILITIES161.9280.4352.9418.7497592.6709.9854.319.3
    TOTAL677.91175.814821760.42092.42498.32996.73611.419.5

    REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS36.863.979.191.8106.7124.5145.9171.716.8
    HOSPITALS & SPECIALTY CLINICS10.918.822.926.330.334.940.547.115.5
    LONG-TERM CARE FACILITIES14.725.331.135.841.347.955.765.216
    TOTAL62.5108133.1154178.3207.3242.128416.4

    Target Audience

    • Pharmaceutical Manufacturers : Develop market entry strategies and product portfolios tailored to European regulatory requirements and patient preferences for oral protein and peptide therapeutics with country-specific demand forecasts.
    • Biotech Companies : Identify licensing opportunities, partnership prospects, and commercialization pathways for oral delivery technologies across Europe's diverse healthcare markets and reimbursement landscapes.
    • Healthcare Investors & PE Firms : Evaluate investment opportunities in European oral protein companies and delivery technology platforms with detailed market sizing, growth trajectories, and exit potential analysis by country.
    • Contract Manufacturing Organizations : Understand regional demand for oral protein and peptide manufacturing capabilities, identify capacity expansion opportunities, and align production strategies with European market growth projections.
    • Healthcare Consultants & Advisors : Support client advisory services with comprehensive European market intelligence, competitive benchmarking, and strategic recommendations for oral therapeutics market participation and expansion.

    Key Companies in the Europe Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 5880.7 Million · 24.1% wtd CAGR ·
    Asia Pacific
    ~USD 1135 Million · 17.2% wtd CAGR ·
    Latin America
    ~USD 650.7 Million · 13.9% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 1418.6 Million
    UKUSD 884.5 Million
    FranceUSD 391.9 Million
    ItalyUSD 247.4 Million
    SpainUSD 147.8 Million
    NetherlandsUSD 98.9 Million
    Rest Of EuropeUSD 244.4 Million

    Country market size visualization

    Germany
    USD 1418.6 Million
    UK
    USD 884.5 Million
    France
    USD 391.9 Million
    Italy
    USD 247.4 Million
    Spain
    USD 147.8 Million
    Netherlands
    USD 98.9 Million
    Rest Of Europe
    USD 244.4 Million

    Reasons to Buy this Report

    • Regional Market Segmentation : Gain detailed insights into Europe's oral proteins and peptides market with country-level breakdowns including Germany, UK, France, Italy, Spain, and Netherlands, enabling precise market targeting and localized strategy development.
    • Competitive Landscape Analysis : Understand the competitive dynamics specific to Europe's pharmaceutical sector, including key players, market consolidation trends, and differentiation strategies within the oral delivery space.
    • Regulatory & Compliance Insights : Access comprehensive analysis of European regulatory frameworks (EMA, national authorities) affecting oral protein and peptide approvals, market entry timelines, and compliance requirements across jurisdictions.
    • Growth Opportunity Identification : Identify high-potential market segments and therapeutic areas within Europe's oral proteins market, including emerging applications in diabetes, GI disorders, and immunology with specific growth projections.
    • Strategic Investment Guidance : Leverage detailed market forecasts and trend analysis to inform investment decisions, partnership opportunities, and expansion strategies within Europe's fastest-growing pharmaceutical delivery segment.

    Frequently asked questions

    What is the current size of Europe's oral proteins & peptides market?

    Europe's oral proteins & peptides market is valued at USD 1,226.7 million in 2025 and is projected to reach USD 3,180.3 million by 2030.

    What is the expected growth rate for Europe's oral proteins & peptides market?

    Europe's oral proteins & peptides market is expected to grow at a compound annual growth rate (CAGR) of 21.0% from 2025 to 2030.

    What factors are driving growth in Europe's oral proteins & peptides market?

    Key drivers include Europe's aging population, rising prevalence of chronic diseases, advanced healthcare infrastructure, regulatory support, and significant biotech investment in oral delivery technologies.

    Which European countries are leading the oral proteins & peptides market?

    Europe's market is led by countries with strong pharmaceutical and biotech sectors, including Germany, France, the United Kingdom, and Switzerland, which have robust regulatory frameworks and R&D capabilities.

    What challenges does Europe's oral proteins & peptides market face?

    Challenges include bioavailability and stability issues with oral protein formulations, stringent EU regulatory requirements, manufacturing complexity, and competition from alternative delivery methods.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status